Topical Antiangiogenic SRPK1 Inhibitors Reduce Choroidal Neovascularization in Rodent Models of Exudative AMD | Zendy

Melissa V. Gammons | Zendy; O. Fedorov | Zendy; David Ivison | Zendy; Chunyun Du | Zendy; Tamsyn Clark | Zendy; Claire Hopkins | Zendy; Masatoshi Hagiwara | Zendy; Andrew D. Dick | Zendy; Russell J. Cox | Zendy; Steven J. Harper | Zendy; Jules C. Hancox | Zendy; Stefan Knapp | Zendy; David O. Bates | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Topical Antiangiogenic SRPK1 Inhibitors Reduce Choroidal Neovascularization in Rodent Models of Exudative AMD

Author(s) -

Melissa V. Gammons,

O. Fedorov,

David Ivison,

Chunyun Du,

Tamsyn Clark,

Claire Hopkins,

Masatoshi Hagiwara,

Andrew D. Dick,

Russell J. Cox,

Steven J. Harper,

Jules C. Hancox,

Stefan Knapp,

David O. Bates

Publication year - 2013

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.13-12422

Subject(s) - choroidal neovascularization , in vivo , pharmacology , angiogenesis , alternative splicing , kinase , neovascularization , serine , chemistry , vascular endothelial growth factor , rna splicing , phosphorylation , gene isoform , cancer research , biology , retinal , biochemistry , vegf receptors , gene , genetics , rna

Exudative AMD (wet AMD) is treated by monthly injection into the eye of anti-VEGF proteins. VEGF is alternatively spliced to produce numerous isoforms that differ in angiogenic activity. Serine-rich protein kinase-1 (SRPK1) has been identified as a regulator of pro-angiogenic VEGF splicing by phosphorylating serine-rich splicing factor-1 (SRSF1), which binds to VEGF pre-mRNA. We tested the hypothesis that topical (eye drop) SRPK1-selective inhibitors could be generated that reduce pro-angiogenic isoforms, and prevent choroidal neovascularization in vivo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research